Featured Opinions
Left out of the show, yet commanding the circus
by Anonymous (not verified)
When you talk to most SFE experts in the industry, no matter where you might begin, the conversation eventually comes around to the importance of ongoing training and coaching.
Social Media for Legal and Regulatory
After attending a recent pharma conference via Twitter I once again heard that some of the biggest obstacles to implementing social media are regulatory and legal people.
Speak now or forever hold your peace
by Anonymous (not verified)
Do we change or are we changed?
Numerous sources, newsletters and blogs like this indicate or tell us that the *habitat of the pharmaceutical industry* no longer is what it used to be. Pharma
Off label marketing is it really worth the price?
by Anonymous (not verified)
The how to fix Patient Compliance now series* *
by Anonymous (not verified)
Understanding paid search and ROI
More U.S. adults use the Internet than doctors for obtaining health and medical information.
Forecasting is too important to be left to forecasters
by Annie M
Last week we bade farewell to Michelle, our forecasting specialist. We had a small party for her, with champagne and nuts, which was rather nice.
Pharma runs and hides from paid search
According to a study from web metrics measurement firm ComScore, paid search ads by pharmaceutical companies dropped a whopping 84% between March 26 of this year and the end of June. Does thi
Will younger doctors be more resistant to drug company blandishments?
by Alison Bass
A week or so ago, I gave a talk to about 120 senior citizens at Brandeis University's Lifelong Learning Institute.
by Anonymous (not verified)
The pharmaceutical sector has been dogged by decades of excesses which have diminished the need for strategy.
To regulate or not to regulate?
Over the last decade, the amount of regulation the industry is dealing with has been on a predictable upward trend.
by Anonymous (not verified)
Recruiting sales professionals with the right attributes to quickly become top producers is more important than ever in these challenging economic conditions.
How to make the patient compliance concept more useful NOW - Step #2.
Differentiate unintentional from intentional noncompliance. This is the second in a series of posts offering steps to improve the study of and communication about patient compliance. <
The red face test - would our senior executives pass?
So much has been said and written about unethical behaviour amongst executives in the financial sector. This has been a source of embarrassment for many of them.
Launching a new product without TV and on smaller budgets
With DTC spending down by double digits a lot of DTC marketers are going to be facing the reality of doing more with less next year.
What would happen if all companies got rid of their sales force. Admittedly we are talking about the prospect of thousands of jobs disappearing, but more importantly would the customers miss them?
How to make the patient compliance concept more useful NOW - Step #1.
Include context-pertinent definitions of terms. Bringing down the current concept of patient compliance and replacing it with a functional set of principles is taking for-freaking-eve
by Anonymous (not verified)
Today marks the launch of eyeforpharma's newest newsletter, which will focus exclusively on market access. It's a topic that we've touched on for some time, but that we feel is becoming so important to pharma's future success that it deserves a newsletter all to itself.